3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
88
Phase 1
61
Phase 1/2
47
Phase 3
19
Phase 2/3
6
Phase EARLY_PHASE1
4
Phase NA
3
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma
1
Glioblastoma
1
Interventions
raltitrexed
1
pembrolizumab
1
methylnaltrexone
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Paclitaxel
1
Immune Checkpoint Inhibitors
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Squamous Cell Carcinoma of Head and Neck
×
pembrolizumab
×
Clear all
NCT04489888
2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4
Completed
101 enrolled
14 charts